Tor-Arne Hagve
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tor-Arne Hagve has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Torbjørn Omland
K.G. Jebsen Center for Cardiac Biomarkers, Institute of Clinical Medicine, University of Oslo , Oslo
3 shared publications - Vidar Søyseth
Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3 shared publications - Arne Didrik Høiseth
A Division of Medicine , Akershus University Hospital , Lørenskog , Norway
2 shared publications - Pål Haugar Brekke
Oslo University Hospital,Center for Cardiological Innovation,Oslo,Norway
2 shared publications - Gunnar Einvik
Department of Pulmonology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway
1 shared publication Ingrid Marie Hardang
1 shared publication
Latest Publications
- 6 January 2023
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 143 (1)
Utredning av hyperferritinemi
06.01.2023: Fra laboratoriet - Høyt ferritinnivå i plasma med eller uten jernoverskudd sees ved en rekke kliniske tilstander.
- 6 January 2023
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 143 (1)
Utredning av hyperferritinemi
06.01.2023: Fra laboratoriet - Høyt ferritinnivå i plasma med eller uten jernoverskudd sees ved en rekke kliniske tilstander.
- Open Access
- 1 November 2022
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 22 (1) , 1-8
It is unlikely that oxygen supplementation in COPD patients with chronic respiratory failure reduce cardiac troponin level
Cardiac troponin T (cTnT) is a biomarker of myocardial injury frequently elevated in COPD patients, potentially because of hypoxemia. This non-randomised observational study investigates whether long-term oxygen treatment (LTOT) reduces the cTnT level. We compared cTnT between COPD patients who were candidates for LTOT (n = 20) with two reference groups. Patients from both reference groups were matched with the index group using propensity score.Reference groups consists of institutional pulmonary rehabilitation patients (short-term group) (n = 105 after matching n = 11) and outpatients at a pulmonary rehabilitation clinic (long-term group)(n = 62 after matching n = 10). Comparison was done within 24 h after LTOT initiation in first reference group and within 6 months after inclusion in the second group. The geometric mean of (standard deviation in parentheses) cTnT decreased from 17.8 (2.3) ng/L (between 8 and 9 a.m.) to 15.4 (2.5) ng/L between 1 and 2 p.m. in the LTOT group, and from 18.4 (4.8) ng/L to15.4 (2.5) ng/L in group (1) The corresponding long-term results were 17.0 (2.9) ng/L at inclusion (between 10 and 12 a.m.) to 18.4 (2.4) ng/L after 3 months in the LTOT-group, and from 14.0 (2.4) ng/L to 15.4 (2.5) ng/L after 6 months in group (2) None of the differences in cTnT during the follow-up between the LTOT-group and their matched references were significant. Initiation of LTOT was not associated with an early or sustained reduction in cTnT after treatment with oxygen supplementation.
- 1 November 2022
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 22 (1) , 1-8
Open AccessIt is unlikely that oxygen supplementation in COPD patients with chronic respiratory failure reduce cardiac troponin level
Cardiac troponin T (cTnT) is a biomarker of myocardial injury frequently elevated in COPD patients, potentially because of hypoxemia. This non-randomised observational study investigates whether long-term oxygen treatment (LTOT) reduces the cTnT level. We compared cTnT between COPD patients who were candidates for LTOT (n = 20) with two reference groups. Patients from both reference groups were matched with the index group using propensity score.Reference groups consists of institutional pulmonary rehabilitation patients (short-term group) (n = 105 after matching n = 11) and outpatients at a pulmonary rehabilitation clinic (long-term group)(n = 62 after matching n = 10). Comparison was done within 24 h after LTOT initiation in first reference group and within 6 months after inclusion in the second group. The geometric mean of (standard deviation in parentheses) cTnT decreased from 17.8 (2.3) ng/L (between 8 and 9 a.m.) to 15.4 (2.5) ng/L between 1 and 2 p.m. in the LTOT group, and from 18.4 (4.8) ng/L to15.4 (2.5) ng/L in group (1) The corresponding long-term results were 17.0 (2.9) ng/L at inclusion (between 10 and 12 a.m.) to 18.4 (2.4) ng/L after 3 months in the LTOT-group, and from 14.0 (2.4) ng/L to 15.4 (2.5) ng/L after 6 months in group (2) None of the differences in cTnT during the follow-up between the LTOT-group and their matched references were significant. Initiation of LTOT was not associated with an early or sustained reduction in cTnT after treatment with oxygen supplementation.
- Open Access
- 18 September 2017
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 137 (17)
Anemi ved kronisk sykdom
Klinisk oversikt - Anemi ved kronisk sykdom er i Vesten den vanligste formen for anemi hos hospitaliserte pasienter over 50 år.
- 18 September 2017
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 137 (17)
Open AccessAnemi ved kronisk sykdom
Klinisk oversikt - Anemi ved kronisk sykdom er i Vesten den vanligste formen for anemi hos hospitaliserte pasienter over 50 år.
- Open Access
- 6 July 2012
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 12 (1) , 22
Determinants of high-sensitivity cardiac troponin T during acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study
A high-sensitivity cardiac troponin T (hs-cTnT) concentration above the 99th percentile (i.e. 14 ng/L) is common during Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) and associated with increased mortality. The objective of the study was to identify factors associated with hs-cTnT levels during AECOPD.
- 6 July 2012
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 12 (1) , 22
Open AccessDeterminants of high-sensitivity cardiac troponin T during acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study
A high-sensitivity cardiac troponin T (hs-cTnT) concentration above the 99th percentile (i.e. 14 ng/L) is common during Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) and associated with increased mortality. The objective of the study was to identify factors associated with hs-cTnT levels during AECOPD.
- Open Access
- 1 January 2012
- Published by Springer Nature in Respiratory Research
- Vol. 13 (1) , 97
NT-proBNP independently predicts long term mortality after acute exacerbation of COPD – a prospective cohort study
Cardiovascular disease is prevalent and frequently unrecognized in patients with chronic obstructive pulmonary disease (COPD). NT-proBNP is an established risk factor in patients with heart failure. NT-proBNP may also be released from the right ventricle. Thus serum NT-proBNP may be elevated during acute exacerbations of COPD (AECOPD). The prognostic value of NT-proBNP in patients hospitalized with AECOPD is sparsely studied. Our objective was to test the hypothesis that NT-proBNP independently predicts long term mortality following AECOPD.
- 1 January 2012
- Published by Springer Nature in Respiratory Research
- Vol. 13 (1) , 97
Open AccessNT-proBNP independently predicts long term mortality after acute exacerbation of COPD – a prospective cohort study
Cardiovascular disease is prevalent and frequently unrecognized in patients with chronic obstructive pulmonary disease (COPD). NT-proBNP is an established risk factor in patients with heart failure. NT-proBNP may also be released from the right ventricle. Thus serum NT-proBNP may be elevated during acute exacerbations of COPD (AECOPD). The prognostic value of NT-proBNP in patients hospitalized with AECOPD is sparsely studied. Our objective was to test the hypothesis that NT-proBNP independently predicts long term mortality following AECOPD.